Replication stress arises from many sources, and the review methodically maps them. Oncogene activation is a principal culprit. When growth-promoting signals such as MYC or cyclin E are unleashed, they push cells through the cell cycle faster than replication machinery can be properly licensed, forcing replication to begin in inappropriate places. Shortened G1 phases leave origin licensing incomplete, and transcription programs fire at full blast while forks attempt to copy the same sequences. The resulting collisions between replication and transcription complexes are among the most potent sources of chromosome breakage, particularly at long, highly transcribed genes known as common fragile sites, which have been recognized as breakage hotspots since experiments with the polymerase inhibitor aphidicolin in the 1980s.

Transcription-replication conflicts come in mechanistically distinct flavors. Head-on conflicts, where the replication fork meets an oncoming RNA polymerase, and co-directional conflicts produce different R-loop levels and activate different DNA damage responses. R-loops, three-stranded structures containing an RNA-DNA hybrid and a displaced single strand, have emerged as pivotal intermediates that can either protect or poison genomes depending on how they are resolved. Studies of BRCA1 and BRCA2 have shown that these breast and ovarian cancer tumor suppressors do more than repair double-strand breaks; they actively suppress R-loop accumulation by coordinating transcription elongation and RNA processing. Similarly, chromatin remodelers such as the SWI/SNF complex and spliceosome factors help clear conflicts, explaining why mutations in these complexes, common in myelodysplastic syndromes and Ewing sarcoma, produce cells exquisitely sensitive to ATR inhibition.

Beyond collisions, the review highlights metabolic and structural pressures. Nucleotide pools are a striking example: early work demonstrated that deoxyribonucleotide deficiency distorts origin choice and spacing, while later studies showed that oncogene-induced senescence is partly a consequence of nucleotide starvation. Cancer cells also accumulate unprocessed uracil and ribonucleotides in DNA, both of which impede fork progression. DNA secondary structures add another layer. Unstable inverted repeats fold into hairpins and cruciforms, and expanded TA-dinucleotide repeats in microsatellite-unstable colorectal cancers form structures that grind forks to a halt. These repetitive obstacles, rather than mismatch repair failure alone, are now understood to be why such tumours become fatally dependent on the WRN helicase, which unwinds these structures and prevents catastrophic chromosome shattering.

The consequences of unresolved replication stress reverberate through the cancer genome. Stalled forks are vulnerable to nuclease degradation unless BRCA2 protects the nascent DNA, and collapse generates breaks that drive chromosomal instability, linking structural and numerical chromosome chaos. Under-replicated regions persist into mitosis, producing anaphase bridges, micronuclei and copy-number changes that mirror the polymorphic and pathogenic variants seen in human populations. Several avenues of rescue have been characterized, including fork reversal, repriming by the PRIMPOL primase-polymerase and specialized translesion polymerases that replicate past damaged bases, but these repair routes are intrinsically error-prone. Translesion synthesis underlies acquired chemotherapy resistance, and repriming leaves single-stranded DNA gaps that, recent work shows, are a key determinant of PARP inhibitor sensitivity in BRCA-deficient cells.

The ATR-CHK1 checkpoint pathway is the master guardian that keeps replication stress survivable. ATR is recruited to RPA-coated single-stranded DNA through its partner ATRIP and activated by TopBP1 or ETAA1, with the MRN complex and the 9-1-1 clamp sharpening its activation. Once active, ATR suppresses excess origin firing, stabilizes stalled forks, enforces an intrinsic S/G2 checkpoint that prevents cells from entering mitosis with unfinished replication, and prevents global exhaustion of RPA, a failure mode that culminates in replication catastrophe and genome fragmentation. Without ATR, forks collapse and single-stranded DNA accumulates beyond rescue, a finding that transformed the enzyme from a basic research curiosity into a top-priority drug target.

That targeting has now reached the clinic. ATR inhibitors such as ceralasertib and elimusertib have produced durable responses in tumours with high replication stress, including small cell lung cancer, and synthetic lethal combinations with ATM loss, ERCC1 deficiency, CCNE1 amplification and APOBEC3 activity are being pursued. WEE1 inhibitors override the G2 checkpoint and force stressed cells into lethal mitosis, with combination strategies including sequential PARP and WEE1 dosing designed to minimize toxicity. The clearest success story remains PARP inhibition, introduced in landmark 2005 studies demonstrating synthetic lethality in BRCA-mutant cells. Mechanistic work has since refined the model: PARP inhibitors trap PARP1 and PARP2 on DNA and act through persistent single-stranded gaps that BRCA-deficient cells cannot fill, and next-generation PARP1-selective agents such as AZD5305 promise better tolerability. WRN inhibition in microsatellite-unstable cancers represents the newest synthetic lethal frontier, with resistance mechanisms beginning to be mapped by CRISPR screens.

The review also reframes replication stress as a chronic, sublethal condition that sculpts tumour evolution over years rather than an acute lethal event. This slow burn generates mutational signatures, including those of APOBEC3 cytidine deaminases, that fuel heterogeneity, therapy resistance and metastasis, and therapy itself can amplify APOBEC3A-driven evolution in persistent cancer cells. Importantly, replication stress intersects with the immune system. Under-replicated DNA in micronuclei activates the cGAS-STING pathway, and chromosomal instability promotes metastasis through cytosolic DNA sensing, while SAMHD1 and MYC normally suppress inflammatory signaling from replication-derived nucleic acids. ATR inhibition can potentiate the inflammatory tumour microenvironment, opening rational combinations with immune checkpoint blockade, an approach already validated in microsatellite-unstable and BRCA-mutated tumour settings.

The authors position replication stress not as a single weakness but as a dynamic, context-dependent vulnerability landscape shaped by each tumour’s oncogenic, metabolic and chromatin state. Biomarkers such as replication stress signatures, gap formation and fork protection status may soon guide which patients receive ATR, WEE1, PARP or WRN inhibitors, and in which combinations. The therapeutic opportunity, they argue, lies in recognizing that tumours pay a permanent price for their genomic chaos, and that the rescue pathways they depend upon are now precisely druggable targets.

Subject of Research: Replication stress in cancer: origins, consequences and therapeutic opportunities

Article Title: Replication stress in cancer: origins, consequences and therapeutic opportunities

Article References: Chen, J., & Zou, L. (2026). Replication stress in cancer: origins, consequences and therapeutic opportunities. Nature Reviews Cancer. https://doi.org/10.1038/s41568-026-00979-z

Image Credits: AI Generated

DOI: 10.1038/s41568-026-00979-z

Keywords: replication stress, cancer, ATR, CHK1, PARP inhibitors, synthetic lethality, R-loops, genomic instability, WRN helicase, WEE1 inhibitors, precision oncology, DNA replication

ATR, short for ataxia-telangiectasia and Rad3-related, belongs to the PIKK family of giant kinases that also includes ATM, DNA-PKcs, mTOR and SMG1. Like its siblings, ATR is an enormous HEAT-repeat scaffold carrying a kinase domain buried deep within, and it operates as a dimer paired with its obligate partner ATRIP. Since the first cryo-EM structures of human ATR–ATRIP appeared in 2018, researchers have known the complex’s overall architecture but not the physical choreography of its activation. The central puzzle has been phosphorylation: ATR autophosphorylates itself, and this modification is considered a hallmark of the active kinase, yet nobody had seen structurally what phosphorylation does to the machine or how the activator protein TopBP1 drives the process. The new study addresses that gap directly by trapping the complex at successive stages of its catalytic cycle.

The team began with precatalytic snapshots. In two structures determined with the non-hydrolysable ATP analogue ATPγS wedged in the active site, they found that nucleotide binding alone accomplishes something remarkable: it primes the catalytic center for chemistry without wholesale rearrangement of the kinase domain. When the researchers then added a fragment of Chk1, the key downstream effector of the ATR pathway, the substrate docked neatly onto the primed enzyme. In other words, ATP binding and substrate positioning can proceed as relatively independent, modest steps rather than requiring a dramatic conformational detonation. This finding revises the textbook expectation that PIKK kinases need massive global movements to become catalytically competent, and it suggests that the rate-limiting event in ATR activation lies elsewhere — specifically, in the regulatory rearrangements triggered by TopBP1.

That TopBP1-dependent rearrangement is the structural centerpiece of the paper. In the activated structure, two molecules of TopBP1 bind simultaneously to the ATR–ATRIP dimer, one engaging each protomer from opposite faces. TopBP1 latches onto the HEAT-repeat scaffold far from the active site, and in doing so it locks the N-HEAT and M-HEAT domains of ATR together in both protomers. In the precatalytic and substrate-bound states, these scaffold elements make intimate contact in one protomer while hovering apart in the other — an inherent asymmetry. TopBP1 binding abolishes that asymmetry, snapping the dimer into a near-symmetric conformation that promotes ATR–ATRIP autophosphorylation and drives efficient phosphorylation of Chk1. Detailed atomic contacts reveal how this is achieved: an intensive network of hydrogen bonds welds a TopBP1 beta strand to the M-HEAT domain, the tryptophan residue W1145 of TopBP1 buries into a hydrophobic pocket at the N-HEAT/M-HEAT junction, and salt-bridge interactions fasten a TopBP1 helix onto the N-HEAT superhelix.

Perhaps the most provocative observation concerns what happens after activation. The researchers purified ATR–ATRIP complexes that had been fully autophosphorylated in the presence of TopBP1, then stripped the activator away and determined the structure of the phosphorylated kinase on its own. Remarkably, the phosphorylated complex remained fully competent to phosphorylate Chk1, and it did so regardless of how much TopBP1 was added back. Structurally, the released enzyme adopted an asymmetric conformation, yet its kinase domain was essentially indistinguishable from that of the TopBP1-bound, near-symmetric activated state. The authors conclude that catalytic activity is compatible with both near-symmetric and asymmetric architectures, meaning that phosphorylation — not a rigid, TopBP1-imposed symmetry — is the true durable switch. Once ATR has phosphorylated itself, the checkpoint engine keeps running even if its ignition key is removed, a property with clear implications for how sustained checkpoint signaling is maintained at damaged replication forks.

The autophosphorylation story was reinforced biochemically. Mass spectrometry mapped dozens of newly phosphorylated sites on ATR and ATRIP, and phosphatase treatment confirmed that the mobility shifts seen in gels were genuinely phosphorylation-dependent. Activity assays showed a clean dose-response: non-phosphorylated ATR–ATRIP phosphorylated Chk1 only when TopBP1 was titrated in, whereas the pre-phosphorylated complex catalyzed Chk1 modification at TopBP1 concentrations approaching zero. Interestingly, an isolated ATR head domain displayed only basal activity with or without TopBP1, underscoring that the full dimeric scaffold — and its TopBP1-driven reorganization — is required to reach full catalytic power. Together these experiments elevate ATR autophosphorylation from a correlative biomarker to a mechanistically demonstrated molecular switch for checkpoint activation.

The paper’s second act concerns therapy. ATR inhibitors such as berzosertib (VX-970/M6620), ceralasertib (AZD6738), gartisertib (VX-803/M4344) and elimusertib (BAY 1895344) are in clinical development as sensitizers that push tumor cells with pre-existing DNA repair defects over the edge. The team determined four separate inhibitor-bound structures of ATR–ATRIP, one for each compound, providing the first side-by-side atomic views of how this pharmacological class occupies the ATR active site. The nucleotide-binding pocket turns out to be divisible into four sub-compartments: an adenine-binding pocket lined by residues including M2325, Y2365, I2377, W2379 and V2380; an inner hydrophobic pocket; a ribose-binding site; and a triphosphate-binding site. All four inhibitors anchor themselves in the adenine pocket, but each then exploits the pocket’s flexibility differently, extending flanking chemical groups into the hydrophobic cavity, the ribose site, or the triphosphate region.

These structures explain both potency and selectivity. ATR’s adenine and hydrophobic sub-pockets are shifted toward the C-lobe relative to the corresponding sites in DNA-PKcs, mTOR and ATM, a displacement caused by the bulky side chains of M2325 and V2493 in ATR. Inhibitors can therefore nestle into an ATR-specific geometry that the closely related PIKK kinases cannot accommodate. Superimposition with structures of DNA-PKcs, mTOR and ATM further showed that a key hydrogen bond formed by berzosertib with glycine 2385 of ATR would be sterically blocked by the larger residues occupying the equivalent positions in the sibling kinases. In effect, the drugs exploit the conformational plasticity of the ATR active site — the very same flexibility that allows ATPγS to prime the kinase — to achieve multipocket engagement that favors ATR over its family members. For medicinal chemists, the four structures amount to a comparative map of which sub-pockets each clinical candidate touches, a starting grid for designing next-generation inhibitors with improved selectivity and resistance profiles.

Taken together, the study delivers a structural framework in which ATR regulation can finally be read as a sequence of physically defined events. ATP binding primes the catalytic cleft and positions Chk1; TopBP1 binding to the HEAT scaffold reorganizes the dimer and licenses autophosphorylation; phosphorylation converts the enzyme into a durably active state that survives TopBP1 dissociation; and small molecules shut the whole system down by wedging into the plastic ATP pocket. The work also resonates with parallel findings on ATM, where asymmetric activation of the dimeric kinase has recently been visualized, hinting at shared regulatory logic across the PIKK family. For cancer biology, the implications are tangible: tumors rely obsessively on ATR to survive their own replication chaos, and a structure-level understanding of both the activation switch and the drug-binding pocket should accelerate the design of inhibitors that hit ATR harder and more selectively. As ATR inhibitors advance through clinical trials, the molecular movie assembled by Wang, Cheng, Qiao and colleagues provides the kind of mechanistic blueprint on which the next generation of checkpoint-targeted therapies can be drawn.

Subject of Research: Cryo-EM structural mechanisms of phosphorylation-driven activation and inhibitor binding of the human ATR–ATRIP checkpoint kinase complex

Article Title: Mechanistic insights into phosphorylation-driven activation and therapeutic inhibition of human ATR–ATRIP

Article References: Wang, L., Wang, M., Zhao, L., Rao, Q., Wu, H., Ma, B., Wang, J., Zheng, J., Li, Y., Xu, Y., Guo, J., Cheng, J., & Qiao, S. (2026). Mechanistic insights into phosphorylation-driven activation and therapeutic inhibition of human ATR–ATRIP. Nature Structural & Molecular Biology. https://doi.org/10.1038/s41594-026-01887-4

Image Credits: AI Generated

DOI: 10.1038/s41594-026-01887-4

Keywords: ATR, ATRIP, TopBP1, Chk1, cryo-electron microscopy, DNA damage response, replication stress, autophosphorylation, kinase activation, ATR inhibitors, berzosertib, cancer therapy